Systematic review and meta-analysis of 2,722 adults with malignant neoplasms shows intravenous vitamin C significantly prolongs overall survival compared to controls.
Pooled median survival ratio for overall survival was 1.83 (95% CI: 1.40-2.40), indicating a nearly doubled median survival time.
Progression-free survival showed a favorable trend but did not reach statistical significance.
Subgroup analyses suggest benefits are more pronounced with lower vitamin C doses and in certain regional and combination therapy contexts.
